C
CDXS
Codexis Inc
1.280
-0.030-2.29%After Hours: 1.300 +0.020 +1.56%19:27 10/23 EDT
OPEN/PREV CLOSE1.300/1.310
TODAY RANGE1.265-1.320
VOL546.63K
MARKET CAP140.17M
52 WEEK RANGE0.9583-2.980
AVG VOL (3M)996.90K
% TURNOVER0.41%
TURNOVER--
P/E (TTM)-3.7780
% RANGE4.20%
EPS(TTM)-0.3388
P/E(FORWARD)-3.3684
P/B3.550
BVPS0.3606
DIVIDEND--
P/S1.645
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP130.21M
SHARES OUTSTANDING109.51M
NEXT EARNINGS11/04-11/09
FREE FLOAT101.73M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·4d ago
Piper Sandler Sticks to Their Buy Rating for Codexis (CDXS)
Seeking Alpha·09/28 11:02
Codexis partners with siRNA drug innovator for enzymatic oligonucleotide synthesis
Dow Jones·09/28 11:00
Codexis Shares Gain on Agreement With Undisclosed Drug Innovator
TipRanks·09/28 10:20
Codexis announces agreement with siRNA drug innovator
TipRanks·09/22 12:56
Codexis (CDXS) Has a New Rating from Stephens
TipRanks·08/20 00:27
Codexis Earnings Call: Margin Gains, Scale-Up Bets
Dow Jones·08/17 16:15
Codexis Price Target Cut to $8.00/Share From $9.00 by Piper Sandler
Dow Jones·08/17 16:15
Codexis Is Maintained at Overweight by Piper Sandler
Benzinga·08/17 16:05
Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8
NASDAQ·08/14 16:00
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Simply Wall St·08/12 22:45
Codexis (CDXS) Stock Rallies On Longer Cash Runway Questions Remain
TipRanks·08/12 14:35
Cantor Fitzgerald Keeps Their Buy Rating on Codexis (CDXS)